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https://doi.org/10.1016/j.celrep.2020.107550SUMMARYAlthough thousands of solid tumors have been sequenced to date, a fundamental under-sampling bias is
inherent in current methodologies. This is caused by a tissue sample input of fixed dimensions (e.g., 6 mm
biopsy), which becomes grossly under-powered as tumor volume scales. Here, we demonstrate representa-
tive sequencing (Rep-Seq) as a newmethod to achieve unbiased tumor tissue sampling. Rep-Seq uses fixed
residual tumor material, which is homogenized and subjected to next-generation sequencing. Analysis of in-
tratumor tumor mutation burden (TMB) variability shows a high level of misclassification using current single-
biopsy methods, with 20% of lung and 52% of bladder tumors having at least one biopsy with high TMB but
low clonal TMB overall. Misclassification rates by contrast are reduced to 2% (lung) and 4% (bladder) when a
more representative sampling methodology is used. Rep-Seq offers an improved sampling protocol for tu-
mor profiling, with significant potential for improved clinical utility andmore accurate deconvolution of clonal
structure.INTRODUCTION
Over the past decade, clinical researchers have demonstrated
the inability of an individual biopsy or formalin-fixed paraffin-
embedded (FFPE) block to capture the genetic diversity of a
solid tumor (Turajlic et al., 2018; Jamal-Hanjani et al., 2017; War-
rick et al., 2019). This issue stems from the reliance on single-site
samples, which are used as the current standard protocol for tu-
mor sequencing in both research and clinical contexts. Sampling
only once, from a single spatial location, will miss major expand-
ing tumor subclones in other distant tumor locations, creating a
bias that cannot be resolved through excess sequencing depth.
Moreover, this widespread sampling bias is inherently obscured
because the unsampled fixed tumor tissue not submitted forThis is an open access article under the CC BY-Nparaffin embedding is considered surgical waste and is inciner-
ated. The pitfalls of using a non-representative sampling method
are well documented in the ‘‘theory of sampling’’ developed by
Pierre Gy (Gy, 1988) and have been practically demonstrated
across multiple fields, ranging from food contamination to elec-
toral polling and the mining industry (Rohde et al., 2015; Crespi,
1988; David, 1988). In the case of tumor sequencing, this
bias arises within the context of spatially biased intratumor
heterogeneity (ITH) as an important feature of cancer, combined
with the increasing utility of molecular profiling as a tool to
stratify patients for therapy (AACR Project GENIE Consortium,
2017). Failure to address this issue risks undermining the
clinical utility of genomic medicine in cancer, through reduced
sensitivity to detect prognostic and predictive markers, a lackCell Reports 31, 107550, May 5, 2020 ª 2020 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Current Tumor Sequencing Methods Lead to Under-sampling, Which Can Be Resolved through a Wider Sampling Frame
(A) Top: a density plot of the distribution of tumor volumes from The Cancer Genome Atlas (TCGA), with tumor volume (cubic centimeters) plotted on the x axis
with log scale. Middle: a density plot of the volume of biopsy tissue used as input material for sequencing in the same cohort of TCGA samples. Bottom: the
proportion of tissue sampled (i.e., values from the middle panel divided by those from the top panel for each case), split by tumor stage.
(B) Left: the estimated tumor volume (cubic centimeters) from a clinical audit, split by tissue site. Right: the proportion of tissue sampled, split by tissue site, in the
clinical audit.
(C) The experimental design used for pilot experiment of pooled ‘‘cocktail’’ samples.
(D) Left: the variant allele frequency (VAF) correlation between cocktail sequencing (x axis) compared with true VAFs estimated from multi-biopsy sequencing
(y axis); right: the variant allele frequency (VAF) correlation between single-region sequencing (x axis) compared with true VAFs estimated from multi-biopsy
sequencing (y axis).
(legend continued on next page)
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OPEN ACCESSof reproducibility in sequencing results among samples, misas-
signment of subclonal variants as clonal (Pearson et al., 2016),
and unreliable estimates of tumor mutation burden (TMB). A
frequently proposed solution is to conduct multi-region sampling
and profiling, which although able to address these issues in a
research setting is cost prohibitive and too labor intensive for
wide-scale adoption in clinical practice. Furthermore, the recur-
rent question of how many biopsies should be taken is unan-
swerable because of the high variability in ITH among patients
(Turajlic et al., 2018). We hypothesized that a new sampling
methodology could be implemented to circumvent these limita-
tions, through the use of residual tumor tissue to create a more
representative sample that captures the heterogeneity of the to-
tal tumor mass. We show that this new method better captures
the diversity of the tumor and leads to improved biomarker re-
sults, without the need for increased sequencing depth or for
multiple samples to be profiled per tumor. Furthermore, as the
method described herein removes the physical bias of single-
sample profiling and makes use of residual fixed tumor material
that would otherwise be clinical waste, it empowers clinicians
and researchers with a practical solution to overcome sampling
bias within current tumor sequencing protocols.
RESULTS
Audit of Current Sampling Protocols
To examine the extent of current under-sampling bias in cancer
genomics, we first analyzed pan-cancer sequencing data from
The Cancer Genome Atlas (TCGA). Clinical annotation files
were extracted for each solid tumor cohort from the Broad Insti-
tute’s TCGAGDAC Firehose repository, fromwhich tumor length
and width data were available for 1,667 samples across six tu-
mor types (STAR Methods). For each sample, total tumor tissue
volume and research sample volume were estimated from the
clinical data, and the two values were compared to assess the
proportion of total tumor mass sampled for each case (STAR
Methods). This revealed that current research protocols sample
on average only 2.3% of the tumor mass (median value for all
stages, n = 1,667 samples), decreasing to 0.5% for stage IV tu-
mors (median value, n = 181) (Figure 1A). We next investigated
this pattern within a routine clinical context, through audit of
randomly selected cases undergoing molecular profiling as
part of standard of care at a major cancer center (see STAR
Methods). In total, 76 cases were audited, across three different
solid tumor types. This revealed a median clinical tumor sam-
pling proportion of only 0.0005% (range 0.000001%–0.2%) (Fig-
ure 1B), reflecting the minimal input material provided from stan-
dard FFPE tumor sections. The remaining R99.9% of tumor
tissue is left unsampled for molecular profiling purposes, leading
to a high level of under-sampling in a clinical context. Thus,
within both research and clinical settings, current tumor
sequencing protocols are associatedwith a high under-sampling(E) Left: data from 100 non-small cell lung cancer cases, with clonal tumor mutatio
within the same case are joined by gray line). Right: the same data, this timewith cl
lines denote cases for which one paired value is below the 10 muts/Mb thresho
mutations.
(F) Urothelial carcinoma data from 23 patients, following the same format as (E).bias. Furthermore, we note that sampling bias is also likely to be
affected by the level of heterogeneity and the purity of tumor cells
in the sample (Figure S1).
A More Representative Sample Leads to Increased
Ability toDetect Variants and ImprovedAccuracy in TMB
Estimation
To investigate the effect of spatial bias in single-biopsy sampling,
we first conducted a pilot experiment, creating a single, more
representative sample by pooling extracted DNA from 1,184
multi-region biopsies, taken from 79 primary renal cell carci-
nomas (RCCs), to create ‘‘cocktail’’ solutions per tumor (Fig-
ure 1C). Pooled cocktail samples were subject to next-genera-
tion sequencing (NGS) (median depth 6743), and mutation
calls were compared with previously generated single-biopsy
(reflecting current clinical practice; median depth 6083) and
multi-region biopsy (truth set) data (median depth 6123) (Turajlic
et al., 2018). Multi-region variant allele frequencies (VAFs) were
determined by taking the mean across all regions per tumor,
and single-region samples were selected by random sampling
(see STAR Methods). All samples were processed through an
identical protocol (see STAR Methods). Across all 79 tumors,
the cocktail samples discovered a median of 100% (range
30%–100%) of the truth-set mutations compared with single bi-
opsies, which achieved a median discovery rate of 73% (range
15%–100%), supporting the hypothesis that a more representa-
tive sample leads to improved ability to detect variants (p = 6.63
1011, pairedWilcoxon test; Figure S2). In addition, VAFs derived
from cocktail samples demonstrated a strong correlation with
true VAF values from multi-region sequencing (r = 0.97), a supe-
rior correlation compared with that achieved by single-biopsy
sampling (r = 0.69) (Figure 1D). This suggests that using a single,
more representative sample provides a more accurate estima-
tion of true cellular mutational prevalence across the total tumor
mass (the true search space), an important consideration for
both prognostic and predictive biomarkers. Within this context,
TMB is emerging as a robust predictive biomarker for immune
checkpoint inhibitor (CPI) therapy, validated across multiple tu-
mor types (Forde et al., 2018; Hellmann et al., 2018; Snyder
et al., 2014; Mariathasan et al., 2018). In particular clonal muta-
tion load (clonal TMB) has been shown to be the key driver of
CPI response (McGranahan et al., 2016; Miao et al., 2018),
with subclonal mutations likely playing a neutral or negative
role in achieving a sustained anti-tumor immune response (Gej-
man et al., 2018). To explore this further in the context of tumor
sampling, we analyzed multi-region TRACERx non-small cell
lung cancer (NSCLC) (Jamal-Hanjani et al., 2017) and urothelial
carcinoma (UC) (Lamy et al., 2016; Thomsen et al., 2016) data-
sets and found high levels of intratumor TMB variability. In total,
20%of NSCLC cases (n = 100) and 52%of UC cases (n = 23) had
one or more single biopsies with high TMB but low clonal TMB
overall (on the basis of the prospectively validated 10.0n burden (TMB) values compared with single-biopsy TMB values (paired values
onal TMB comparedwith TMBestimates from in silico ‘‘cocktail’’ sampling. Red
ld and one is above. The 10 muts/Mb threshold is defined as 200 missense
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Figure 2. Representative Sequencing Method
(A) The methodological workflow for Representative Sequencing (Rep-Seq).
(B) The sampling strategy for case RS1, for validation of the Rep-Seq method against extensive biopsy sampling.
(C) The map of non-synonymous variants discovered in RS1, across tumor biopsies, ctDNA samples, and Rep-Seq biological replicates. PEACPLF is a cfDNA
taken from pleural fluid, and PEACPTF is a cfDNA taken from peritoneal fluid, both at the time of rapid autopsy, and ctDNA is a pooled sample of P1/P10/P16/P20
timepoints.
(D) Jaccard similarity index results, as ameasure of reproducibility, for single-biopsy sequencing versusRep-Seq (left) and ctDNA sequencing versusRep-Seq (right).
(E) The variant allele frequency (VAF) of mutations detected in RS1 Rep-Seq (dark blue) compared with VAF for the same mutation in the whole RS1 tumor
(calculated as an average across all biopsies).
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ures 1E and 1F). These variability rates, in contrast, were
reduced to 2% (NSCLC) and 4% (UC) when we generated in sil-
ico ‘‘cocktail’’ solutions and predicted clonal TMB (from the sin-
gle cocktail sample; see STAR Methods), highlighting the poten-
tial clinical utility of a more representative sample in reducing the
risk for TMBmisclassification (Figures 1E and 1F). Finally, we as-
sessed the ability of cocktail sequencing to determine clonal
versus subclonal somatic copy number alterations (SCNAs), us-
ing the primary RCC dataset (n = 79). Known RCC clonal events
(Turajlic et al., 2018) (e.g., loss of 3p25.3 and gain of 5q35.3) were
found to have higher logR (log2 ratio of coverage for tumor versus
matched normal samples) than other (predominantly) subclonal
alterations (Figure S2), indicating that clonal and subclonal
SCNA events may be distinguishable in a pooled sequencing
approach.4 Cell Reports 31, 107550, May 5, 2020Homogenization of Residual Tumor Material to Create a
Truly Representative Sample
Next, we next sought to develop an updated tumor sampling
methodology that was consistent with the theory of sampling
(Gy, 1988) and suitable for clinical adoption (i.e., not reliant on
resource-intensive multiple-biopsy sampling and DNA extrac-
tion, as required for cocktail sampling). Here we demonstrate a
new method called ‘‘representative sequencing’’ (Rep-Seq),
which comprises homogenization of solid tumor masses into
well-mixed solutions, coupled with NGS (Figure 2A). Tumor
masses were sourced as the entire residual tumor material not
taken for pathology assessment following surgery, material
that would otherwise have been treated as clinical waste and de-
stroyed (per College of American Pathologists and Royal College
of Pathologists guidelines) or bio-banked. Residual samples
represented on average 54.8% of the total tumor volume and
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our pilot cohort of cases; see Table S1). These values are a sig-
nificant increase over the average of 0.0005% sampled, and
0.0001 g of tumor tissue, currently used as sampling input in
standard molecular profiling approaches. Following dissection
of the formalin-fixed residual tumor tissue away from the sur-
rounding normal tissue, the residual tumor mass is homogenized
into a representative solution. From this well-mixed solution,
samples are drawn for DNA extraction, library preparation, and
sequencing (Figure 2A). Rep-Seq was implemented on a proof-
of-concept basis in 11 tumors, from four different cancer types
(Table S1).
Reproducibility and Sensitivity of Rep-Seq Compared
with Biopsy Sequencing
The first tumor processed was RS1, a large clear cell RCC
(ccRCC) tumor (17 cm maximal dimension), selected to allow
extensive sampling for cross-validation purposes. In total, 64
fresh-frozen individual biopsies were taken from the primary tu-
mor, and the remaining formalin-fixed residual mass (1,258 g of
tissue) was homogenized under the Rep-Seq protocol. To define
the variant landscape in this tumor, whole-exome sequencing
(WES) was first conducted on a selection of 7 spatially disparate
primary biopsies and an aliquot of the Rep-Seq sample (median
depth 1623), leading to the discovery of a total of 76 non-synon-
ymous mutations (single-nucleotide variants [SNVs] and small-
scale insertion/deletions). These 76 mutations were subse-
quently captured in a targeted custom panel and successfully
sequenced to high depth (median depth > 10,0003) in the 64 pri-
mary biopsies, 11 biopsies taken from two lymph node (LN) me-
tastases, four separate aliquots drawn from the representative
homogenate of the primary tumor sample (biological replicates),
six circulating tumor DNA (ctDNA) samples collected at different
time points, and three homogenized LN Rep-Seq samples (one
LN was not biopsied) (Figure 2B). This integrated dataset was
used to comprehensively evaluate the Rep-Seq methodology
(Figure 2C). First we evaluated the reproducibility of each
method, comparing the Jaccard similarity index between pair-
wise combinations of tumor biopsies, versus pairwise biological
replicates of Rep-Seq, and pairwise combinations of ctDNA time
points. Median pairwise similarity between biopsies was 0.78,
suggesting that approximately 20–25% of mutations discovered
in individual biopsies cannot be reproduced in subsequent bi-
opsy samples. In contrast, median similarity among Rep-Seq
replicates was higher at 0.95 (Figure 2D), with almost identical
mutation lists discovered by each replicate (Figure 2C). Pairwise
similarity among plasma ctDNA sampleswas low (overall median
similarity index = 0.24; Figures 2C and 2D), reflecting the tech-
nical challenges of ctDNA profiling. The ongoing temporal evolu-
tion of the tumor across ctDNA time points should also be recog-
nized, but we note substantial difference even among samples
drawn close time points (e.g., P16 and P20 were only 21 days
apart but shared no mutations in common). Last, we assessed
the sensitivity of variant detection in case RS1 and note that var-
iants as low as 0.15% VAF were successfully detected in the
Rep-Seq sample (Figure 2E). In addition, the VAFs from Rep-
Seq closely followed the overall tumor VAFs, as measured
from the set of 64 biopsies (overall tumor VAF was calculatedas total alt read count/total read count, summed across all bi-
opsies) (Figure 2E). Only 3 mutations (of the 76 captured) were
not detectable in the Rep-Seq sample, all with VAFs below
0.3%, close to the technical limit of0.1%VAF for variant detec-
tion using NGS protocols.
Clonal Structure Prediction from Rep-Seq Compared
with Biopsy Sequencing
Next, we investigated the utility of Rep-Seq in determining clonal
structure, given that measures of clonal diversity have been
shown to associate with prognosis (Turajlic et al., 2018; McGra-
nahan et al., 2016). Cancer cell fraction (CCF) estimates were
first calculated for all mutations (n = 76) within the RS1 primary
tumor biopsy set (n = 52 biopsies used, n = 12 excluded because
of low purity; see STAR Methods) and grouped together into
mutational clusters to infer a high-confidence benchmark clonal
structure. Four distinct tumor clones were detected: clone A
(truncal clone, mutations in every cancer cell, CCF = 100.0%,
n = 41 mutations) and (sub)clones B (CCF = 45.6%, n = 2 muta-
tions, and 14q loss as a known RCC driver SCNA event; Turajlic
et al., 2018), C (CCF = 52.8%, n = 6 mutations), and D (CCF =
17.1%, n = 2 mutations) (Figure 3A). The remaining mutations
were predominantly lower frequency and could not be reliably
clustered into subclones. The clustering process was repeated
for the Rep-Seq sample alone (n = 1), and the clonal solution
was then compared between methods (Figure 3A). Rep-Seq
correctly clustered all 41 clonal mutations together into truncal
clone A (CCF = 100.0%), as well as identifying two major (sub)
clones, B (CCF = 40.6%) and C (CCF = 33.3%) (Figure 3A) (we
note that the sets of mutations in subclones B and C were not
fully identical between the multi-region and Rep-Seq solutions).
The remaining mutations in the Rep-Seq sample were again pre-
dominantly lower frequency and could not be reliably clustered,
reflecting the challenge in accurately grouping together low-CCF
mutations. CCF estimates from both methods were validated
against physical mapping of spatial biopsy locations and muta-
tional presence back to images of the sampled tumor: (sub)clone
Bwas found in 20 of 52 primary biopsies (38.4%), and (sub)clone
C was found in 32 of 52 (61.5%) (Figure 3B). This confirmed the
presence of two major, spatially distinct subclones. Intriguingly,
LN metastases LN1 and LN2 were exclusively seeded by clone
B, whereas spatially proximal peri-renal LN sample LN(PR) was
polyclonal, with clones B and C present. Individual mutation
CCFs within each sample were next considered, in order to
assess how well separated truncal events (clone A) were from
subclonal mutations (clones B and C). Within the Rep-Seq sam-
ple, CCF estimates for clonal events (clone A) were clearly sepa-
rated from (sub)clones B and C, reflecting the rapid convergence
of CCF estimates in Rep-Seq toward true values (Figure 3C,
right). In contrast, CCF distributions in single-sample biopsies
overlapped among clones A, B, and C, with sub(clones) B and
C frequently appearing (incorrectly) as clonal in individual bi-
opsies with CCFs of 100% (‘‘illusion of clonality’’; Burrell and
Swanton, 2016). On average across the 52 primary biopsies,
17% (range 6%–35%) of clonal variants suffered from an illusion
of clonality, if they were considered a single-region sample (Fig-
ure 3D) (all 76 mutations included; see STAR Methods). An illu-
sion of clonality persisted even with multi-region biopsyCell Reports 31, 107550, May 5, 2020 5
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Figure 3. Clonal Tracking by Rep-Seq and ctDNA in Renal Cell Carcinoma
(A) The phylogenetic tree for case RS1, as derived using extensive multiple-biopsy sequencing (left) and a single Rep-Seq sample.
(B) The clonal distribution across the four slices of the primary RS1 tumor and lymph node metastases.
(C) The cancer cell fraction (CCF) estimates for mutations in tumor clones A, B, and C in each biopsy sample (left) and in the Rep-Seq sample (right).
(D) The illusion of clonality simulation data, with the number of simulated biopsy samples plotted on the x axis and the percentage of variants that incorrectly
appear to be clonal (illusion of clonality) on the y axis (from 100 simulated sample combinations).
(E) ctDNA data for RS1, with the VAFs plotted (y axis) for mutations in clones A, B, and C.
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yielded an illusion of clonality rate of 9% (range 0%–25%), three
of 6% (range 0%–25%), four of 4% (range 0%–15%), and five of
3% (range 0%–15%) (Figure 3D). Furthermore these results are
likely to represent a conservative under-estimation of true illu-
sion of clonality rates, as 3-dimensional sampling was conduct-
ed along the z axis in this case.We note that if standard 2-dimen-
sional tumor slice sampling had been conducted only on slice 4,
which was monoclonal for clone C, no number of biopsies would
have prevented clonal illusion (Figure 3B), and critically, clone B
(which metastasized to the LNs) would have been completely
missed.
Given the broad applicability of liquid biopsies, and previous
work demonstrating that both clonal and subclonal mutations
can be identified (Abbosh et al., 2017), a pertinent question is6 Cell Reports 31, 107550, May 5, 2020to what extent ctDNA samples from plasma represent true clonal
diversity compared with a more representative sampling of the
primary tumor. Taking advantage of a well-characterized primary
tumor, and five longitudinal ctDNA time points, we investigated
this question. At pre-surgery time points (P1 and P10), variants
from clones A, B, and C were all detectable at VAFs of 0.1%–
1.0%, but many variants were missed, including some clone A
truncal events, reflecting the technical challenges of profiling
ctDNA. Mean VAF within clone A was overall higher than within
(sub)clones B and C, but large inconsistency was observed in
terms of individual variants analyzed across time points (Fig-
ure 3E). At post-surgery time point P16, the highest VAF variant
was from clone C, and similarly at time point P20, a clone B mu-
tation was highest, both above any clone A truncal mutations
(Figure 3E). At later stage time points, however (post-mortem
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consistent VAF frequency (Figure 3E). Correlation coefficients
of VAFs from ctDNA, compared with the count of how many bi-
opsies a mutation was present in, ranged from r = 0.17 (time
point P16) to r = 0.78 (pleural fluid obtained post-mortem).
Rep-Seq CCFs had the highest correlation with biopsy count
data (r = 0.90). This suggests that inferring de novo clonal struc-
ture from ctDNA alone remains challenging, but tracking clonal
markers that have been previously identified from tumor tissue
remains highly informative (e.g., for minimal residual disease
[MRD] tracking). We note, in the context of MRD tracking, that
a larger panel of variants is likely to increase sensitivity to detect
relapse at earlier time points (e.g., in the RS1 data at time point
p16, an MRD panel based on mutations from a single biopsy
would have missed disease relapse 53% of the time, compared
with a 0%miss rate using a Rep-Seq-based panel; Table S2). In
terms of the clonal dynamics of RS1, an interesting pattern was
observed, with clone C dying out at later ctDNA time points and
becoming undetectable (Figure 3E). This supports the predicted
metastatic seeding pattern, as determined by biopsy and Rep-
Seq profiling, that is, that clone B achieved distal metastatic
seeding, whereas clone C was contained within the (peri-)renal
area (Figure 3B). As an additional validation, copy number anal-
ysis was conducted on 31 further biopsies sampled from 20
distinct anatomical sites of metastatic disease present at the
time of RS1 autopsy. All sites contained loss of 14q, a driver
event found only in clone B in the primary tumor (Figure S3).
We note that in single-region biopsy sequencing, metastasizing
clone B would have been missed 32 times out of 52 (61.5%).
Rep-Seq Implemented on Lymph Node Samples in the
Context of Metastatic Melanoma
To understand the utility of Rep-Seq profiling on LN residual ma-
terial (asopposed toRS1, forwhicha largeprimary tumorwasalso
available), we homogenized two LN samples (internal iliac LN and
right inguinal LN) from a patient with metastatic melanoma (case
RS2). In parallel, single-biopsy LN (right inguinal LN) sequencing
was additionally conducted (biopsy taken prior to homogeniza-
tion), as well as multi-region biopsies sequenced from a further
eight distinct anatomical sites of metastases, in order to validate
the Rep-Seqmethodology (total n = 17 samples). All samples un-
derwent WES (median coverage 2003), with tissue sampled at
the time of rapid autopsy (STAR Methods). The first question
was to compare the results from LNRep-Seqwith those from sin-
gle-sample LN sequencing, which would be the standard sam-
pling approach in the context of a LN dissection. CCF clustering
analysis was completed for the LN single sample (see STAR
Methods; Figure 4A), and the calculated tree was monoclonal in
structure (100% of mutations were predicted clonal, n = 90). Re-
sults from the homogenized Rep-Seq LN sample, in contrast,
calculated a polyclonal tumor structure, with only 63% of muta-
tions (n = 58) being clonal and the remainingmutations (n = 34) be-
ing subclonal, clustered into four distinct subclones (Figures 4B
and 4C). To verify which solutionwas correct (mono- versus poly-
clonal), a joint clustering analysiswascompleted across all biopsy
samples (n = 16 from LN and eight distal metastases) to yield a
high-confidence clonal solution (Figure 4D). The tumor was
indeed found to be polyclonal, with a total of seven distinct tumorsubclones detected (Figure 4D). A major branch encompassing
multiple distinct subclones (Figure 4D, far left of tree) was found
to be shared across pelvic, liver, paravertebral, abdominal wall,
loin soft tissue, and supra-renal metastases but was absent in
two distinct right groin soft tissue masses (Figure 4D). The right
groin masses were each characterized by distinct tumor sub-
clones (Figure 4D). A number of individual sites were also found
to be polyclonal in nature (e.g., liver, paravertebral mass) contain-
ing both themajor left-handsubclone branch and the distinct sub-
clones present in the right groin masses (Figure 4D). These poly-
phyletic patterns would be consistent with either polyclonal
dissemination from the primary or metastasis-to-metastasis
seeding.Wenote that not all tumor subclonesweredetectable us-
ing the Rep-Seq LN methodology, but the representative sam-
pling methodology was accurate enough to clearly distinguish
this asapolyclonal tumor,witha lowerproportionofmutationsbe-
ing clonal. This finding was supported by extensive sampling of
multiple metastases. The single-site sample, in contrast, incor-
rectly predicted a monoclonal tumor structure, with all mutations
being clonal in nature. Clinically, we note that this patient received
three lines of immune CPI therapy (adjuvant nivolumab, ipilimu-
mab, and pembrolizumab) and failed to respond throughout,
with progressive disease recorded for all rounds and sites of
CPI treatment (Figure 4E). Although only descriptive in nature,
this lack of response would be consistent with the hypothesis of
a heterogeneous subclonal neoantigen repertoire being associ-
ated with poor response to immunotherapy (Wolf et al., 2019).
For completeness, we additionally obtained archival FFPE blocks
for the RS2 primary tumor sample, and at median 2003
sequencing coverage, none of the metastasizing clones were
detectable, highlighting thechallenge ofmelanomaprimary tissue
sampling where the tumor size is so small.
Rep-Seq Implemented on an Extended Cohort of
Primary Solid Tumors across Four Tissue Types
The Rep-Seqmethod was additionally conducted in a further ten
cases as a technical feasibility exercise. Cases RS3 and RS4
were ccRCC tumors and predominantly monoclonal in structure
(Figure S4). Cases RS5–RS11 were tumors of breast, colorectal,
and lung origin, and tumor-specific driver mutations were suc-
cessfully detected in all specimens (Table S3). The highest
mutation burden was observed in RS8 (colon), with 980 and
251 non-synonymous SNVs and indels and presence of cosmic
mutational signatures 6 and 15 associated with mismatch repair
deficiency (Figure 5A), which was confirmed by immunohisto-
chemistry staining showing loss of MLH1. Signature analysis of
the three NSCLC tumors (RS9, RS10, and RS11) showed evi-
dence of signature 4 (smoking associated) uniquely in these
three tumors only (Figure 5A). Hence the mutational signatures
derived from Rep-Seq were consistent with expected patterns.
Tumor Purity-Enriched Rep-Seq Protocol
Finally, an additional benefit of tissue homogenization is the
preservation of the cellular integrity of the tissue and therefore
the ability to add a cell-sorting step prior to DNA purification,
to enrich for higher tumor purity. As a proof of principle, flow sort-
ing was conducted on RS12 (colorectal tumor), preferentially
selecting isolated tumor nuclei on the basis of the presence ofCell Reports 31, 107550, May 5, 2020 7
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Figure 4. Clonal Tracking by Rep-Seq in Metastatic Melanoma
(A) The phylogenetic tree for case RS2 using single-biopsy lymph node sequencing (right inguinal LN).
(B) The phylogenetic tree for case RS2 using Rep-Seq LN sequencing.
(C) The proportion of mutations, clonal and subclonal, in RS2 on the basis of single-biopsy (top) and Rep-Seq (bottom) profiling.
(D) The extended phylogenetic tree for caseRS2, on the basis of joint clustering of LN and eight distalmetastases samples. Clone presence ismarked on the basis
of anatomical site of disease, with absent clones in a given site shaded in lighter color. Note that the right inguinal LN now becomes subclonal in composition,
because of the benefit of multi-region joint clustering. Previously in (A), these same mutations are incorrectly clustered to the truncal clone (illusion of clonality)
because of the limitations of single-biopsy sampling.
(E) The clinical history of case RS2. The best response by RECIST version 1.1 criteria is denoted in parentheses. SD, stable disease; PD, progressive disease.
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OPEN ACCESScytokeratins 8 and 18 and high forward/side scattering. WES
was conducted, first on a standard sample from the Rep-Seq
protocol (non-sorted Rep-Seq, depth 2213), which showed tu-
mor purity of 0.44. Strong enrichment was observed in the
flow-sorted Rep-Seq sample (depth 2153), with purity of 0.89,
which resulted in an approximate doubling of the effective tumor
cell sequencing coverage (from 903 to 1843), for the same over-
all bulk sample sequencing depth and cost (Figure 5B). In terms
of variant discovery, 365 non-synonymous SNVs were observed
in common between both standard and flow-sorted samples,
and then an additional 68 mutations (an increase of 19%) were
found uniquely in the flow-sorted sample, presumably because
of the increased sensitivity from higher effective tumor depth
(Figure 5B). Only 5 mutations (1.4% of the total, all with VAFs <
5%) were found with the opposite pattern (i.e., in the standard
sample but missing in the flow-sorted sample), which suggests
in this case that flow sorting did not create systematic bias8 Cell Reports 31, 107550, May 5, 2020such that certain tumor subclones are excluded. The additional
sensitivity in mutation detection enabled a larger set of sub-
clones to be defined (Figure 5C).
DISCUSSION
Here we present Rep-Seq as a newmethod to achieve unbiased
tumor sampling, drawing DNA molecules from a well-mixed ho-
mogenized solution of all residual surgical tumor material. This
method removes the spatial bias inherent in current single-
biopsy approaches and significantly increases the probability
of detecting the genomic heterogeneity of solid tumors in a single
sample protocol. Successful delivery of precision medicine in
oncology is contingent on a reliable identification of biomarkers.
ITH affects the interpretation of prognostic biomarkers and pre-
dictive biomarkers of response to targeted and immunotherapy,
most notably TMB. Rep-Seq offers a clear opportunity to
AB
C
Figure 5. ExtendedRep-SeqCohort and Tu-
mor Purity Enrichment
(A) Non-synonymous mutation count for cases
RS5–RS11 (top), along with mutational signature
analysis results (bottom).
(B) Left: RS12 coverage data for the overall bulk
mixed cell population and then an estimated tumor
cell coverage, along with purity estimates. Data
are shown for standard Rep-Seq, and then tumor
purity-enriched Rep-Seq, for comparison pur-
poses. Right: the number of non-synonymous
variants detected in normal and purity-enriched
Rep-Seq samples. Variant counts are color coded
on the basis of either being ‘‘shared’’ (i.e., present
in both samples) or ‘‘private’’ (i.e., variant is pre-
sent in only that sample and absent from the
other).
(C) Phylogenetic trees for the normal and flow-
sorted RS12 tumor subclones.
Resource
ll
OPEN ACCESSovercome the issue of ITH in these contexts and could feasibly
be adopted in routine clinical practice.
In our analysis we first show the extent of under-sampling in
current research studies, with data from TCGA demonstrating
an average tissue sampling proportion of 2.3%. This bias is
evenmore pronounced in a routine clinical context, with our audit
data from standard molecular profiling at a major cancer center
demonstrating that only five cancer cells in every million
(0.0005%) are being sampled. This rate of under-sampling raisesthe risk for misinterpreting clinically rele-
vant tumor sequencing results, asdemon-
strated by a high level of variability in TMB
scores between single sites and the true
clonal mutation load. Indeed, in NSCLC
and UC, we show that 20% and 52% of
cases, respectively, have at least one bi-
opsy classified as high TMB, when the
overall clonal TMB is low. Thismisclassifi-
cation risk canbe reduced throughusinga
more representative sample, with discor-
dance rates being reduced to 2% and
4%, respectively, using in silico ‘‘cocktail’’
analysis. We note, however, that the in sil-
ico ‘‘cocktail’’ samples may have slightly
higher tumor purity than the main Rep-
Seq methodology, as the latter takes all
residual tumor material as input rather
the biopsy-sampled regions.
To address the issue of spatial sam-
pling bias in a manner consistent with
the theory of sampling, as well as the
challenge of multiple-biopsy sampling
being too labor intensive for routine clin-
ical use, we next sought to develop an up-
dated tumor sampling methodology. We
demonstrate Rep-Seq as a new method
able to overcome both these points,
through sampling a large volume of tumortissue (average sampled proportion 55%), but maintaining a sin-
gle (n = 1) DNA sample for downstream NGS library preparation
and sequencing. The source of material in Rep-Seq is unique by
making use of excess residual tumor tissue from surgery, which
would otherwise be destroyed as clinical waste or bio-banked
for research use. Homogenization of this residual tissue makes
an ideal source for DNA extraction and sequencing, given the
more representative nature of the sample, and generates a sub-
stantial amount of material that can be retained for futureCell Reports 31, 107550, May 5, 2020 9
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OPEN ACCESSresearch use. Such practices of homogenized sampling have
been in routine practice in other fields for many decades, such
as the sampling of mineral deposits. This fact, combined with
the large amount tissue processed as clinical waste, highlights
the sub-optimal nature of current molecular profiling sampling
approaches in oncology. Here we demonstrate the utility of
Rep-Seq through extensive sampling in a cohort of pilot cases,
primarily as a proof-of-concept study. We show that the repro-
ducibility in variant detection between replicates in Rep-Seq is
high (Jaccard similarity index = 0.95) and superior to that of sin-
gle-biopsy sequencing (0.78). In case RS1, sampling of >50 bi-
opsies, from five tumor slices, validated the accuracy of Rep-
Seq clonality predictions. In contrast, single-biopsy sequencing
suffered from a high rate of illusion of clonality, with 17% of mu-
tations appearing clonal when in reality they were subclonal.
Conversely, single-biopsy sequencing also frequently missed
important events, with 62% of biopsies missing the metasta-
sizing clone. And notably all biopsies from tumor slice 4 missed
the lethal clone, indicating that even extensive multi-region sam-
pling is still susceptible to spatial bias, unless implemented on a
3-dimensional basis. Ultimately, any biopsy-based sequencing
approach will retain spatial bias to some degree when tumor tis-
sue is left unsampled, which hence emphasizes the benefit of a
homogenization-based sampling approach.
In case RS2, we used Rep-Seq to profile LN metastases from
a patient with primary melanoma, which revealed polyclonal
disease. This was confirmed by extensive biopsy sequencing
of eight further sites of distal metastases, which validated poly-
clonality, with multiple distinct subclones present across
anatomically separate sites. Results from single-biopsy LN
sequencing, in contrast, predicted a monoclonal tumor, which
was shown to be incorrect. With increasing evidence now sup-
porting clonal neoantigens as a key driver of immunotherapy
response (Miao et al., 2018; Gejman et al., 2018), the accurate
delineation of clonal versus subclonal alterations is of clinical
relevance. This is descriptively illustrated in case RS2, in which
lack of response to three lines of immunotherapy was
observed, in the context of a high subclonal neoantigen reper-
toire. We additionally implemented Rep-Seq on a further ten
cases (RS3–RS12), from lung, colorectal, and breast cancer
types, showing mutation rates and signatures in line with ex-
pected results. Finally, as a further extension of the Rep-Seq
protocol, we demonstrate flow sorting as a method to achieve
tumor purity enrichment. For case RS12, purity was increased
from 44% to 89%, with no observed shift or bias introduced
to the sequencing results. Purity enrichment complements
well the homogenization-based Rep-Seq approach and could
significantly reduce sequencing costs (the same equivalent
coverage of tumor cells could have been achieved in half the
cost for case RS12).
We acknowledge small cohort size as a limitation of this
work and confirm that a larger prospective study of Rep-Seq
(n = 500 cases) is under way (ClinicalTrials.gov identifier
NCT03832062). In addition, although Rep-Seq yields accurate
and unbiased estimates of clonal and major subclonal muta-
tions, this comes with the trade-off of losing resolution to
detect lower frequency tumor (sub)clones. This trade-off may
be acceptable in a clinical context, in which lower frequency10 Cell Reports 31, 107550, May 5, 2020mutations may be less directly actionable than widely
expanded clonal or major subclonal driver events. Furthermore,
we show with deep custom panel sequencing in case RS1 that
low-frequency mutations can be reliably detected in Rep-Seq
down to 0.3% VAF, with sensitivity determined by current limits
in NGS accuracy. As more sensitive sequencing assays (e.g.,
duplex sequencing) become adopted, it is likely that Rep-Seq
can be used to search for ultra-low-frequency events. We
also acknowledge that Rep-Seq will not be applicable in all pa-
tient contexts, for example, patients with advanced-stage dis-
ease who undergo only biopsy sampling (no other surgeries).
However, in metastatic cases undergoing resection, as well
as primary surgery, there is broad potential for bio-banking
and homogenization of residual material using the Rep-Seq
approach. Finally, there is also potential scope for hybrid ap-
proaches, in which a large part of the residual material is ho-
mogenized, but then a portion (e.g., a transverse section) is
also retained for spatially dependent analysis (e.g., imaging,
spatial transcriptomics).
In summary, here we implement Rep-Seq as a new tumor
sampling methodology combined with NGS, which adopts a
more representative sampling approach via homogenization of
residual tumor tissue. This method offers a clinically practical so-
lution to the dramatic under-sampling bias inherent in current
molecular profiling workflows. We find the reproducibility of re-
sults in Rep-Seq to be significantly higher than for current sin-
gle-biopsy sequencing approaches (at same equivalent
sequencing depth), and greater accuracy was also achieved in
determining clonal from subclonal variants. We note that these
results are predicted from the theory of sampling, a statistically
driven rule set for sampling solid masses that are heteroge-
neous. These results offer potential clinical utility in the context
of both prognostic (e.g., greater sensitivity to detect metastasis
driving subclones) and predictive biomarkers (e.g., improved
clonal TMB estimates).STAR+METHODS
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Antibodies
Mouse anti-cytokeratin 8/18 antibody Ventana Medical Systems cat # 760-4344; RRID:AB_10583331
Goat-anti-Mouse antibodyconjugated with
Alexa Fluor 488
Invitrogen cat # A11001; RRID:AB_2534069
Goat-anti-Mouse antibody conjugated with
Alexa Fluor 647
Invitrogen cat # A-21236; RRID:AB_141725
Chemicals, Peptides, and Recombinant Proteins
BD FACS Aria Bectin Dickinson cat # 656700
CC1 buffer Ventana Medical Systems cat # 950-124
antibody diluent buffer Ventana Medical Systems cat # 251-018
autoMACS buffer Miltenyi Biotech cat # 130-091-221
phosphate buffered saline Fisher Scientific cat # 14190
Tween 20 Fisher Scientific cat # AC233362500
DAPI Sigma cat #D9542
Pepsin Sigma cat # P7012
Proteinase K VWR cat # 0706
Critical Commercial Assays
cobas cfDNA Sample Preparation Kit Roche 7247737190
AVENIO ctDNA Enrichment Kit Roche 8061041001
AVENIO ctDNA Library Prep Kit Roche 8061050001
HyperCap Target Enrichment Kit, 96 Reactions Roche 8286345001
SeqCap EZ MedExome Enrichment Kit Roche 7681330001
NimbleGen SeqCap Hybridization and Wash Kit Roche 5634253001
HiSeq Rapid SBS Kit v2 Illumina FC-402-4021
HiSeq SBS Kit V4 250 cycle kit Illumina FC-401-4003
xGen Dual Index UMI Adapters IDT N/A
SeqCap EZ Prime Choice Probes- Onco Roche 4000030990- 08247498001
SeqCap EZ Share Choice- Onco Roche 4000007080- 08332975001
SeqCap EZ Custom Design Roche 8332975001
SeqCap Adaptor Kit A Roche 7141530001
HiSeq 2500 Sequencing System Illumina SY-401-2501
cBot System Illumina SY-301-2002
20 micron cell strainer Pluriselect cat # 43-50020-03
IKA disposable grinding chamber IKA-Works cat # MT 40.100
IKA Works Tube Mill Control system IKA-Works cat # 0004180001
Deposited Data
Human reference genome NCBI build 37,
GRCh37
Genome Reference Consortium https://www.ncbi.nlm.nih.gov/projects/
genome/assembly/grc/human/
Rep-Seq data for cases RS1-RS12 This paper European Phenome Genome Archive:
EGAS00001004246
Software and Algorithms
Burrows-Wheeler Aligner (BWA) v0.7.15 Li and Durbin, 2009 http://bio-bwa.sourceforge.net/
Samtools v1.3.1 Li and Durbin, 2009 http://samtools.sourceforge.net/
Picard 1.81 http://broadinstitute.github.io/picard/
(Continued on next page)
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Mutect v1.1.7 Cibulskis et al., 2013 http://software.broadinstitute.org/
cancer/cga/mutect
VarScan v2.4.1 Koboldt et al., 2009 http://varscan.sourceforge.net/
Scalpel v0.5.3 Fang et al., 2016 https://github.com/hanfang/scalpel-protocol
Annovar Wang et al., 2010 http://annovar.openbioinformatics.org/en/latest/
CNVkit v0.7.3 Talevich et al., 2016 https://github.com/etal/cnvkit
R package ‘Copynumber’ Nilsen et al., 2012 http://bioconductor.org/packages/release/
bioc/html/copynumber.html
ABSOLUTE v1.0.6 Carter et al., 2012 http://software.broadinstitute.org/cancer/cga/
absolute
bedtools package Quinlan and Hall, 2010 https://bedtools.readthedocs.io/en/latest/
AlleleCounter N/A https://github.com/cancerit/alleleCount
ASCAT Van Loo et al., 2010 https://github.com/Crick-CancerGenomics/ascat
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Samra
Turajlic (samra.turajlic@crick.ac.uk). This study did not generate new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Clinical studies
Cases RS1, RS3 and RS4 were diagnosed with renal cell carcinoma, and were consented for research under the TRACERx Renal
study (National Health Service Research Ethics Committee approval 11/LO/1996), as previously described5. Autopsy samples
fromRS1 andRS2were obtained through the PEACEStudy (NIHR 18422), where samples are harvestedwithin48 hours fromdeath
(see secondary author list for the full list of PEACE consortium investigators). Residual surgical material for cases RS5, RS6, RS7,
RS8, RS9, RS10, RS11 and RS12 were was obtained from commercial providers of research specimens (GLAS Consultants, Win-
ston-Salem, NC. (IRB#: 120160685) and The MT Group, Van Nuys, CA (MTG-015)) from U.S. hospitals, under IRB approval. Sex/age
of each case is as follows: RS1M/54, RS2M/41, RS3M/75, RS4 F/75, RS5 F/55, RS6 F/81, RS7 F/90, RS8M/65, RS9M/83, RS10 F/
68, RS11 F/75, RS12 (n.a.).
METHOD DETAILS
Clinical audit of current molecular profiling practices
Institutional review board approval was obtained for a service evaluation to quantify the tumor volume routinely profiled as a diag-
nostic standard of care in resected colorectal, melanoma and sarcoma tumors (SE725), where surgery and molecular profiling
were both undertaken at the RoyalMarsdenNHSFoundation Trust was reviewed. Caseswere included if therewere > 2macroscopic
tumor dimensions recorded on the histopathology report and if information was available on the number and thickness of slides used
for molecular profiling. The audit data is shown in Table S4.
Regional biopsy and cocktail sample preparation
Multi and single region biopsy sampling of surgically resected tumor tissue was conducted using the same method as previously
described (Turajlic et al., 2018). Cocktail samples (as displayed in Figure 1) were created for each tumor, by pooling extracted
DNA taken from all single-regions taken for each tumor, in equimolar ratios. A median of 9 single—region samples were pooled
per cocktail. For the autopsy samples from RS1 and RS2, 3mm3 sections were dissected from snap frozen tumor core biopsies
(6mm diameter) and tissue disrupted using the Tissue Raptor. They were then processed through a QIAGEN QIAshredder and
DNA was purified using the QIAGEN All Prep DNA/RNA Mini kit according to manufacturer’s instructions. Germline DNA was ex-
tracted from whole blood or a buffy coat.
Grossing and homogenization of residual tumor tissue
Following diagnostic histologic sampling and removal of fresh biopsies, three distinct clinical surgical waste tissues from a kidney
radical nephrectomy (RS1) containing: 1) a primary tumor, 2) para-aortic lymph node cluster, and 3) renal hilar nodes were fixed inCell Reports 31, 107550, May 5, 2020 e2
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phate-buffered saline (PBS, 14190, Fisher Scientific, USA) for 24 h, then stored in ethanol for until dissected. Tumor tissue was
identified by a pathologist through macroscopic evaluation and physical palpation, and all identifiable tumor was dissected away
from the surrounding tissue. An area of normal tissue (at least 5 cm from the tumor) was also dissected by a pathologist and retained.
Lymph nodes detected during gross examination of the RS1 specimen included hilar and peri-renal nodes were also dissected as an
independent tissue samples. All dissected tissue was weighed prior to homogenization.
Residual primary tumor tissuewas split into two-625 g portions; eachportionwas combinedwith 600mL autoMACSRunningBuffer
(Miltenyi Biotec Inc., 130-091-221) and homogenized in a liquidizer (Cookworks, BL9292E-GS) for 3min at the highest setting. The pri-
mary tumor homogenates (2.5 l total) weremanually combinedandmixed in aplastic container, dividedbackand re-liquidized for addi-
tional homogenization and mixing, and pooled together into a large plastic container. Segregated tissues of renal hilar lymph nodes,
peri-renal node, normal kidney tissue, and para-aortic lymph nodes were each homogenized independently in autoMACS Running
Buffer (1:1,mass: volume) with an IKA TubeMill (IKAWorks Inc.WilmingtonNorth Carolina, 0004180001) for 2min at 15,000 rpmusing
single-use blending containers. When tissue mass exceeded the capacity of an individual blender container, homogenates for the
same sample were pooled by mixing as described above. Samples of each tissue homogenate were stored in methanol (1:1, v:v) at
4C. Case RS2 was lymph-node material from a patient with primary melanoma, and cases RS3 and RS4 were primary renal tumors,
and all were processed through the same homogenization protocol as RS1. For RS2 primary melanoma tissue, the FFPE blocks were
trimmed by razor-blade to remove excess paraffinwax that did not contain any tissue. Remaining wax embedded tissuewas removed
fromFFPEplastic cassette andminced into approximately 1mmcubedpieces using razor blade. Tissue pieceswere deparaffinisedby
5 sequential 1.5 hour 52 degrees’ Celsius xylene washes until all but trace wax was removed and only tissue remained. Xylene was
removed from the sample using a room temperature 10 minute acetone wash followed by three sequential 20 minute 100% ethanol
washes. Ethanol was removed, and the sample hydrated for blending, in two 10 minute sequential washes of 1x PBS.
For cases RS5 to RS12, each specimen had been subjected to standard sampling for diagnosis and staging purposes. These
cases were considered surgical waste and slated for incineration, thus were stored in formalin for four to six weeks. Upon arrival,
tissue was transferred to PBS for 12-24h. Tumor tissue was identified by a pathologist through macroscopic evaluation and physical
palpation, and all identifiable tumor was dissected away from the surrounding tissue. An area of normal tissue (at least 5 cm away
from the tumor) was also dissected by a pathologist and retained. All dissected tissue was weighed prior to homogenization.
Dissected tumor and normal tissue were homogenized separately in single-use blender containers (IKAWorks Inc. Wilmington North
Carolina, 0004180001), or single use consumer grade blenders (Hamilton Beach, 51102, Glen Allen, VA) in autoMACSbuffer (1:1,m:v)
for 2 min at 15,000 rpm or at the highest setting. Resulting homogenates were stored at 4C until further processed.
Genomic DNA purification from tissue and cfDNA
An aliquot of each tissue homogenate (1200 ml) was collected by centrifugation at 5000 rcf. for 2 min, rinsed with TE buffer pH 8.0
(VWR, AAJ62745-EQE) twice, and incubated in 5 mL protease digestion buffer [9.75 mL TE buffer pH 8.0, 60 mg Proteinase K
(VWR, 0706), and 0.25 mL 20% SDS in aqueous solution (Amresco, 0837)] at 56C for 2-16 h. Digested tissue (100 ml) was used
for genomic DNA purification by High Pure PCR Purification Kit (Roche Applied Sciences, Mannheim Germany, 11 732 668 001) ac-
cording to manufacturer’s protocol. Purified genomic DNA was quantified using a NanoDrop 8000 (Thermo Fisher Scientific) and
stored at 20C. cfDNA was isolated from plasma using cobas cfDNA Sample Preparation kit (Roche, 07247737190).
Target-enriched NGS Library construction and sequencing
Illumina compatible indexed NGS libraries were constructed from genomic DNA from tissue using the SeqCap EZ HyperCap Work-
flow User’s Guide, v1.0 (Roche Sequencing Solutions) with notable parameters specified below. Briefly, 1 mg of purified genomic
DNA was enzymatically fragmented for 33-40 min at 37C and prepared for adaptor ligation using the KAPA HyperPlus library
prep kit according tomanufacturer’s instructions (Roche Sequencing Solutions, KK8514). SeqCap sequencing adaptor final reaction
concentration was 2 mM, and adaptor ligation reaction time was extended to 14-18 h, at 16C. No pre-capture PCR was used
following ligation reaction purification. SeqCap EZ library probe baits for either MedExome (07681330001), Onco_EZ
(08333076001), or a custom RS1 specific (see data analysis section below for design criteria) target-enrichment panel (Roche
Sequencing Solutions) and 2 nM blocking oligos (Roche Sequencing Solutions), were incubated for 18-22 h at 47C following manu-
facturer instructions. Post-capture PCR was performed using KAPA HiFi HotStart ReadyMix and LM-PCR oligos for 14 cycles. Post-
capture purified library concentrations were determined by Qubit (ThermoFisher) and fragment size distribution analyzed by Bio-
analyzer 2100 (Agilent). Amplified enriched libraries were each diluted to 2nM and stored at 20C prior to pooling for sequencing.
Pooled libraries were sequenced using MiSeq and HiSeq instruments (Illumina) according to manufacturer’s recommendations for
paired-end sequencing using (Illumina) runs with 101 base paired-end reads. cfDNA sequencing libraries were constructed using the
AVENIO ctDNA Targeted Kit (Roche, 08061076001) by following the AVENIO ctDNA Analysis Kits Reagent Workflow User Guide
v1.0.0. Amplified, adaptor-ligated samples were concentrated together with the Hybridization Supplement using a Vacufuge plus in-
strument (Eppendorf). Each sample was resuspended in the appropriate Enhancing Oligo, the custom RS1-specific panel, and Hy-
bridization master mix. Enrichment, hybridization cleanup and amplification were performed according to manufacturer instructions.
Samples (equal mass) were pooled, and sequenced usingHiseq (Illumina), according to instructions, with 151 base paired-end reads.
Multi-region, cocktail and single regions samples, from 79 renal cell carcinomas as displayed in Figure 1, underwent renal drivere3 Cell Reports 31, 107550, May 5, 2020
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library preparation and sequencing for RS1 was conducted by external laboratory (Eurofins Scientific), using Agilent SureSelect Hu-
man All Exon v5 kits. Multi-region whole exome library preparation for RS2 was conducted at the UCL Pathogen Genomics Unit,
using Agilent SureSelect Human All Exon v5 kits, and sequenced by external laboratory (GENWIZ). Sequencing coverage metrics,
and library kits, for all samples profiled is provided in Table S5.
Flow sorting method to increase tumor purity
A representative sample from formalin fixed residual tumor tissue from RS12 was generated by homogenization in an IKA blender in
autoMACS buffer (1:1 mass to volume). Aliquots of the homogenate (1 g) were further dissociated to individual nuclei by adapting a
previously describedmethod (Hedley et al., 1983). Briefly, tissuewas collected by centrifugation, resuspended in CC1 (VentanaMed-
ical Systems, Tucson, AZ) buffer (5:1 mass to volume), and heated at 80C for 30 min. Tissue was washed once with PBS, and re-
suspended in PBS containing 1 mg/ml proteinase K (1:1 mass to volume) (VWR USA) and incubated at 50C for 10 min. The sample
was exchanged into 5mg/ml pepsin in 150mMNaCl, pH 1.5 (Sigma, USA) and incubated 30min at 37C. The sample was adjusted to
pH 8 with 5 M NaOH, and exchanged into PBS, 0.5% BSA and 0.5% Tween 20 (Fisher Scientific, USA (AC233362500) prior to filtra-
tion through a 20-mm filter (Pluriselect, San Diego, CA) to collect nuclei.
Nuclei were then collected by centrifugation at 400 x g and exchanged into antibody diluent for 30 min at 20C. Samples were
exchanged into mouse anti-cytokeratin 8/18 primary antibody (Ventana Medical Systems, Tucson, AZ) for 1 hour at 4C, washed
three times in 0.5mLPBS, 0.1%BSA and 0.1%Tween 20, and incubated for 30min at 4C in goat-anti-mouse antibodies conjugated
to Alexa Fluor 488 or Alexa Fluor 647 (2 mg/ml) (Invitrogen, San Diego, CA) and DAPI (3 mM) (Sigma, USA). Stained samples were
washed and filtered prior to analysis and sorting using a BD FACS Aria (656700, Bectin Dickinson) equipped with a 355 nm,
60 mW laser and 450/50 nm filter for DAPI; 488 nm, 60 mW laser and 530/30 nm filter for AF 488; and 633 nm, 100 mW laser and
670/30 nm filter for AF 647. No compensation was used. DAPI was used for doublet discrimination. RS11 tumor nuclei were enriched
by FACS after gating to include cytokeratin positive (CK+), high side-scatter (SSC) nuclei and exclude cytokeratin negative (CK-), low
SSC nuclei. The flow cytometry gating strategy is shown in (Figure S5).
QUANTIFICATION AND STATISTICAL ANALYSIS
Tumor volume sampling analysis
For the the clinical audit data, all samples had data on width (W) and length (L) dimensions available, and tumor volume (T_V) was
estimated using the following formula:
T_V =

W2 3 L

2
(taken from the literature as the most accurate tumor volume measurement approach (Faustino-Rocha et al., 2013)).
Biopsy volume (B_V) was calculated based on the 2D surface area analysis of 8 typical slides, with each slide scanned using the
Aperio AT2whole slide scanner at 40x. Each imagewas annotated by hand, following the perimeter of the tissue, and the surface area
calculated via using the Aperio ImageScope software. The average surface area was 3.37cm2 and this value was multiplied by slide
thickness (10 mm), and the total number of slides used, to obtain B_V estimates per tumor.We note that in caseswheremultiple slides
were used for molecular profiling, (up to 5 were used), each slide was taken from the same block (i.e., all from one fixed spatial loca-
tion). The proportion of total tumor volume sampled in each case is then simply calculated as B_V / T_V. For the cancer genome atlas
(TCGA) dataset analysis, we extracted summary clinical annotation files for each solid tumor cohort from the Broad Institute TCGA
GDAC Firehose repository. Tumor dimension data was available for n = 1667 samples, across 6 tumor types: ACC, KICH, KIRC,
KIRP, PAAD and THCA. Tumor volume (T_V) was calculated as per above using the formula: T_V = (W2 3 L) / 2. In cases where
only one dimension was given (i.e., the maximal dimension) this was assumed to be the tumor length, and the tumor width was esti-
mated using a L:W ratio of 1:0.8, with the 0.8 standard value estimated as themedian ratio value observed across all cases with avail-
able length and width data. Biopsy sample volumes were calculated from exact length (L), width (W) and depth (D) dimensions,
as given in the clinical annotation files, with biopsy shape assumed to be cuboid and biopsy volume (B_V) calculated as B_V =
L 3 W 3 D. Where biopsy dimensions were missing in the clinical annotation files, a standard biopsy volume (B_V) of 0.48cm3
was assumed, based on the median value from all other bases where data was available. The proportion of total tumor volume
sampled in each case is then simply calculated as B_V / T_V. In Figure 1A, significance was assessed with a Wilcoxon rank-sum
test. In Figure S1 the intratumor heterogeneity scores, for cases overlapping with the proportion of tumor sampled dataset, were
taken from (Raynaud et al., 2018) (number of clones score). Purity estimates, again for TCGA cases overlapping with the proportion
of tumor volume sampled analysis, were taken from (Aran et al., 2015) (consensus purity estimates).
Processing of sequencing data
Paired-end reads in FastQ format sequenced by MiSeq and Hiseq were aligned to the reference human genome (build hg19), using
the Burrows-Wheeler Aligner (BWA) v0.7.15. with seed recurrences (-c flag) set to 10000 (Li and Durbin, 2009). Intermediate process-
ing of Sam files was performed using Samtools v1.3.1, deduplication was performed using Picard 1.81 (http://broadinstitute.github.Cell Reports 31, 107550, May 5, 2020 e4
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OPEN ACCESSio/picard/) and local indel realignment with GATK v3.6. For whole exome and renal driver Panel_v6 sequencing datasets, single
Nucleotide Variant (SNV) calling was performed using Mutect v1.1.7 and small scale insetion/deletions (INDELs) were called running
VarScan v2.4.1 in somatic modewith aminimum variant frequency (–min-var-freq) of 0.005, a tumor purity estimate (–tumor-purity) of
0.75 and then validated using Scalpel v0.5.3 (scalpel-discovery in - -somatic mode) (intersection between two callers taken) (Cibul-
skis et al., 2013, Fang et al., 2016, Koboldt et al., 2009). SNVs called by Mutect were further filtered using the following criteria: i)
variant allele frequency (VAF)% 1% in the corresponding germline sample, ii) variants that falling into mitochondrial chromosome,
haplotype chromosome, HLA genes or any intergenic region were not considered, iii) presence of both forward and reverse strand
reads supporting the variant. For custom RS1 panel sequencing data, sequencing was conducted at high depth using unique mo-
lecular barcode (UMI) indexes, and UMI-tools (Smith et al., 2017) was used to group PCR duplicates and de-duplicate reads to yield
one read per group. SNVs were then called using deepSNV (Gerstung et al., 2012), as Mutect is known to not be calibrated for higher
sequencing depth levels. Varscan and Scalpel were used to call RS1 custom panel INDELs as described above. All variants were
annotated using Annovar (Wang et al., 2010). To estimate somatic copy number alterations, CNVkit v0.7.3 was performed with
default parameter on paired tumor-normal sequencing data (Talevich et al., 2016). Outliers of the derived logR calls from CNVkit
were detected and modified using Median Absolute Deviation Winsorization before case-specific joint segmentation to identify
genomic segments of constant logR (Nilsen et al., 2012). Tumor sample purity, ploidy and absolute copy number per segment
were estimated using ABSOLUTE v1.0.6 (Carter et al., 2012). Neoantigen predictions were derived by first determining the 4-digit
HLA type for each patient, along with mutations in class I HLA genes, using POLYSOLVER (Shukla et al., 2015). Next, all possible
9, 10 and 11-mer mutant peptides were computed, based on the detected somatic non-synonymous SNV and INDEL mutations
in each sample. Binding affinities of mutant and corresponding wild-type peptides, relevant to the corresponding POLYSOLVER-in-
ferred HLA alleles, were predicted using NetMHCpan (v3.0) and NetMHC (v4.0) (Andreatta and Nielsen, 2016). Neoantigen binders
were defined as IC50 < 50 nM or rank < 2.0. Signature analysis was conducted on all non-synonymous mutations using package de-
constructSigs (Rosenthal et al., 2016).We additionally checked for evidence of formalin induced artifact variants in the Rep-Seq data,
given the protocol involves formalin exposed material. Formalin fixed paraffin embedded (FFPE) samples can contain artifacts, typi-
cally arising due to hydrolytic deamination of cytosine to form uracil, or thymine if the cytosine is methylated. Such artifacts are nor-
mally visible as an excess of C > T/G > A mutations at lower variant allele frequency (Wong et al., 2014). Analysis of this in the whole
exome sequencing data from Rep-Seq cases showed no evidence of excess low frequency formalin induced artifact, with the pro-
portion of low frequency (below 5% VAF) C > T mutations being 34.0%, closely comparable to the average across all base changes
(33.3%) (Figure S5).
Analysis of pooled cocktail sequencing data
The final set of cocktail samples included 79 tumors with matched processed reference datasets frommulti-region sequencing. The
number of biopsies per cocktail sample ranged from 2 to 75with amedian number of 8 biopsies per tumor and a total number of 1,184
individual biopsies. As a reference dataset of true variants, we used previously published multi-region sequencing variant calls from
the same cases, which represented the sum of all variants detected in each tumor (Turajlic et al., 2018). In our analysis we compared
the overall performance of single-region and cocktail sequencing, in detecting somaticmutations from the known truth set. The single
region sample was selected as one random single-region biopsy per tumor, from the overall multi-region dataset. We first evaluated
the performance of the cocktail sequencing approach compared to multi-region and single region sequencing, by comparing the
number of somatic variants detected per tumor with each approach. To reflect the average performance of single region biopsies,
we calculated the mean number of variants detected through single-region sequencing per tumor. We next determined the detection
rates of true variants in the cocktail and the single-region samples using themulti-region sequencing data as a reference. Significance
was assessed with a paired Wilcoxon Test. Finally, in order to establish the accuracy of the cocktail sequencing approach, we next
determined the correlation between the variant allele frequencies (VAF) of all somatic mutations detected through multi-region
sequencing and the VAFs from the cocktail samples as well as a randomly selected single-region biopsy per tumor. The multi-region
VAFs were calculated as the mean VAFs across all regions included in the cocktails. The correlations were calculated with a Spear-
man’s rank-order correlation test.
Analysis of in-silico pooled cocktail sequencing data
For the analysis presented in Figures 1E and 1F, wemade use of two additional multi-region sequencing datasets: i) the TRACERx100
non-small cell lung cancer dataset (Jamal-Hanjani et al., 2017) and ii) a cohort of urothelial carcinomas (Lamy et al., 2016, Thomsen
et al., 2016). Each multi-region sample had undergone whole exome sequencing, as described previously described (Lamy et al.,
2016, Thomsen et al., 2016, Jamal-Hanjani et al., 2017). Sequencing reads were reverted back to fastq format using bam2fastq,
and alignment/variant calling was conducted as described above. The in-silico cocktail samples were created for each case by
down-sampling the reads in each biopsy sample using picard-tools ‘‘DownsampleSam,’’ and then remerging the down-sampled
BAM files to make a merged in-silico cocktail sample. The down-sampling proportion was selected to ensure the merged in-silico
cocktail sample had equivalent coverage to a single biopsy samples for that tumor (e.g., if a tumor had five different biopsy samples
sequenced, a proportion of 0.2 of each BAMwas taken to create a merged file of equivalent depth to a single biopsy). For each data-
set, TMB was measured as the number of missense variants per tumor, with a high TMB threshold of 200 missense mutations used,
which prior analysis has shown is equivalent to the 10 mutations/Mb threshold (synonymous and non-synonymous) derived frome5 Cell Reports 31, 107550, May 5, 2020
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opsy-TMB, based on the number ofmutations in each individual biopsy sample. B) clonal-TMB, based on the full multi-region data for
each tumor, with mutations being judged as clonal by simple ubiquity across all tumor regions. C) Cocktail-TMB, based on the num-
ber of predicted clonal mutations within the in-silico cocktail, with clonality determined by clustering variant allele frequency values
using R function daisy, with the distance matrix computed using Gower’s formula, and the number of clusters set to two (such that
mutations were grouped into either clonal/subclonal groups).
Custom panel design
To conduct in-depth validation of the representative sequencing method high coverage profiling was conducted in case RS1, using a
custom panel. The panel design was based on whole exome sequencing results from: i) 7 biopsies taken from the RS1 primary tumor
(before homogenization) and ii) an aliquot of the RS1 homogenized solution. SNV and INDELmutations were called across the 8 sam-
ples as described above, and a total of 76 non-synonymous mutations were detected (Table S6). These 76 mutations were success-
fully captured in a targeted custom panel, and sequenced to high depth (median > 10,000x) in the 64 primary biopsies, 11 biopsies
taken from 2 lymph node metastases, 4 biological primary Rep-Seq replicates, 6 circulating tumor (ct) DNA samples collected at
different time points, and 3 homogenized lymph node Rep-Seq samples. As an additional validation, all 76 RS1 variants were
also validated using Ion Torrent sequencing, as orthogonal confirmation.
Jaccard reproducibility analysis
The reproducibility of variant discovery between RS1 tumor biopsies, Rep-Seq biological replicates and ctDNA samples was as-
sessed using the Jaccard similarity coefficient. Each pairwise combination between samples (within each group) was considered,
e.g., Biopsy1 (A) versus Biopsy2 (B), Biopsy1 (A) versus Biopsy3 (B), etc. Jaccard similarity coefficient was calculated using the stan-
dard formula (J):
J = M11=ðM01 + M10 + M11Þ
where M11 represents the total number of variants present in both samples A and B, M10 represents the total number of variants pre-
sent in A but not B and M01 represents the total number of variants present in B but not A.
Clustering and phylogenetic analysis
Clustering analysis was performed on cases RS1 (custom panel data) and RS2 (whole exome data) using PyClone Dirichlet pro-
cess clustering (Roth et al., 2014). For each mutation, the observed alternative allele count, reference count and total local tu-
mor copy number was used as input, together with the purity for each sample. PyClone was run with 10,000 iterations and a
burn-in of 1000, and default parameters, with–var_prior total_copy_number. For RS1, two separate PyClone runs were conduct-
ed, the first for the primary multi-region biopsies dataset. Of the total n = 64 primary biopsies sequenced, n = 52 passed quality
control for clustering analysis, with n = 12 biopsies excluded due to lower purity (measured based on purity being too low to call
the known clonal 3p copy number loss event correctly). The second RS1 PyClone clustering run was conducted just for Rep-
Seq homogenate sample alone (n = 1), using the same parameters. Similarly, three separate PyClone runs were conducted for
case RS2, for single biopsy LN sample (alone), Rep-Seq LN sample (alone) and then all biopy samples (from LN and eight other
sites of metastases).
Illusion of clonality simulation
To assess the risk of illusion of clonality, a biopsy sampling approach was simulated, for 1 up to 20 biopsies taken, using the
RS1 datatset. For each biopsy number (n = 1-20), a random sample of biopsies of size n was drawn from the total set of 64
primary biopsies profiled for RS1. Within the random sampled set, the number of mutations which appeared to be clonal (based
on being ubiquitously present in all biopsies in the sampled set) was calculated. This list was then compared to the known list of
truly clonal mutations (from the full 64 set), and percentage of variants which were incorrectly classified as clonal was recorded.
This process was repeated for 100 iterations for each n, to give a distribution, from which mean and standard deviation values
were calculated.
Analysis of purity enriched data
For RS12, whole exome sequencing case conducted using the standard Rep-Seq protocol, and then repeated with the additional
step of flow sorted purity enrichment. Variant calling was completed, and purity estimates calculated in both samples in the same
way, as detailed above. The number of variants discovered in each sample, and then those in common across samples were calcu-
lated and plotted in Figure 5.
Statistical methods
Statistical package R v3.3.2 or higher was used for all analysis. All statistical tests were two-sided. The tests used for each analysis
are listed above in the relevant methods section.Cell Reports 31, 107550, May 5, 2020 e6
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